Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial

We previously reported that in the EMPA-REG OUTCOME(®) trial, empagliflozin added to standard of care reduced the risk of 3-point major adverse cardiovascular events, cardiovascular and all-cause death, and hospitalization for heart failure in patients with type 2 diabetes and high cardiovascular ri...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	European heart journal 2016-05, Vol.37 (19), p.1526-1534
Hauptverfasser:	Fitchett, David, Zinman, Bernard, Wanner, Christoph, Lachin, John M, Hantel, Stefan, Salsali, Afshin, Johansen, Odd Erik, Woerle, Hans J, Broedl, Uli C, Inzucchi, Silvio E
Format:	Artikel
Sprache:	eng
Schlagworte:	Aha Fasttrack Editor's Choice Fast Track
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!